Working… Menu

Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis (AMYDARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02816476
Recruitment Status : Completed
First Posted : June 28, 2016
Last Update Posted : July 9, 2021
Information provided by (Responsible Party):
University Hospital, Limoges

Brief Summary:

This is a Phase II, single-arm, multicentre study of Daratumumab (16mg/kg IV route) in adult patients with Light-Chain (AL) Amyloidosis who are not in VGPR or better after previous treatment. A sample size of 40 patients who meet all eligibility criteria will be enrolled to receive study treatment. Patients will receive treatment until either disease progression or toxicity has occurred with a maximum planned of six 28-day cycles.

Daratumumab will be administrated every week for the first 2 cycles then. every 2 weeks from cycle 3 through cycle 6.

Patients will also receive best supportive care (BSC) to mitigate Daratumumab side-effects, and to address underlying Amyloidosis, including blood product transfusions, antimicrobials, and (as appropriate) growth factors including granulocyte colony-stimulating factors for neutropenia, erythropoietin for anaemia, and/or transfusions for thrombocytopenia

Condition or disease Intervention/treatment Phase
Amyloidosis Drug: Daratumumab Phase 2

Detailed Description:

Systemic AL amyloidosis is a rare disease caused by the deposition of misfolded monoclonal immunoglobulin free light chains (FLC) in various tissues and organs. It is usually associated with a clonal plasma cell dyscrasia with a low tumour burden. Treatment of AL amyloidosis relies mainly on chemotherapy aimed at suppressing the underlying plasma cell clone secreting monoclonal FLC. The organ responses and the survival are greatly influenced by the degree of hematological response evaluated by the decrease in serum FLC that has been the principal endpoint in recent trials in AL amyloidosis. The goal of treatment is to reach at least a very good partial response (VGPR) defined as a difference between the involved FLC and the normal <40 mg/l.

Over the last 2 years, Daratumumab, a novel, high-affinity, therapeutic, human monoclonal antibodies (mAb) that specifically recognizes the CD38 epitope has emerged as a breakthrough targeted therapy for patients with myeloma. Taking into account that, in 90% of AL patients, the monoclonal cells producing amyloidogenic FLC are Cluster of Differentiation 38 (CD38) expressing plasma cells Daratumumab should be a promising treatment in AL amyloidosis.

The study will consist of 4 steps:

  • A 21 day screening period This period start with screening visit which may occurs up to 21 days before the first study drug administration. After signature of the informed consent form, procedures will be performed to ensure patient meet all inclusion/exclusion criteria and document health status to receive study treatment. These assessments will include quality of life questionnaires
  • A treatment period Patient eligible to enter the study will receive 6 cycles of 28 days of intra venous Daratumumab. During cycles 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycles 3 to 6, Daratumumab will be administered every two weeks at days 1 and 15. Patient will have assessments at the ignition of a new cycle to document haematological and organs response and intra cycle to watch for toxicities.
  • An end of study visit (when PD or unacceptable adverse events occurs, or planned end of study visit). Study procedures will be performed at 28 days (± 15) after the last dose of study medication for all patients, including early termination patients.
  • Followup period After treatment discontinuation, followup will be made to the patient every 3 months for at least 1 year to inquire about the patient's hematological and organ status, general health, and information on any new medical events.


Daratumumab. Six 28-day cycles, 16 mg/kg administered by IV route, During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22

For cycles 3 to 6, Daratumumab will be administered every other week at days 1 and 15

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Actual Study Start Date : September 2016
Actual Primary Completion Date : October 5, 2019
Actual Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis
Drug Information available for: Daratumumab

Arm Intervention/treatment
Experimental: Daratumumab
Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
Drug: Daratumumab

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: After 6 cycles treatment (6 months). ]
    Overall Response Rate (CR+VGPR) at the completion of 6 cycles of Daratumumab using the new response criteria (J Clin Oncol, 2012. 30(36): p. 4541-9.

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V4.03. [ Time Frame: Every month during 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be >18 years of age
  2. Histologic diagnosis of AL amyloidosis
  3. Genetic testing must be negative for transthyretin mutations
  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
  5. Patients should have received at least one line with an alkylating agent and/or a proteasome inhibitor and dexamethasone and not be in VGPR or CR at the time of inclusion
  6. Measurable hematologic disease:
  7. Symptomatic organ involvement
  8. Wash-out period of at least 4 weeks from previous antitumor therapy or any investigational treatment or 5 half-lives from previous antibodies, whichever is longer,
  9. Adequate bone marrow function prior to 1st drug intake
  10. Adequate organ function defined as:
  11. Women with childbearing potential must be practicing one of the effective methods of birth control
  12. A man who has not had a vasectomy and who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control
  13. Only patients who are informed of the investigational nature of this study and sign and give written informed consent

Exclusion Criteria:

  1. Amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura as the only evidence of disease. The finding of isolated vascular amyloid in a bone marrow biopsy specimen or in a plasmacytoma is not indicative of systemic amyloidosis
  2. Isolated soft tissue involvement
  3. Presence of non-AL amyloidosis
  4. Bone marrow plasma cells >30% on bone marrow aspirate at screening
  5. Cardiac mayo stage IIIb disease.
  6. Repetitive ventricular arrhythmias on 24h Holter ECG despite anti-arrhythmic treatment, except if a pacemaker has been implanted.
  7. Chronic atrial fibrillation
  8. Supine systolic blood pressure <100 mmHg
  9. Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of any component of the treatment regimen
  10. Clinically overt multiple myeloma with lytic bone lesions
  11. Patients with uncontrolled infection or active malignancy
  12. Any uncontrolled or severe cardiovascular or pulmonary disease
  13. Subjects with psychiatric illnesses or social situations that would preclude them understanding the informed consent, study compliance or the ability to tolerate study procedures and/or study therapy
  14. Subjects with known chronic obstructive pulmonary disease (COPD)
  15. Subject has known moderate or severe persistent asthma within the past 2 years
  16. Previous anti-CD38 therapy
  17. Hypersensitivity to Dexamethasone that would prohibit treatment with study therapy
  18. Known positive for HIV or active hepatitis B or C
  19. Refusal to consent or protected by legal regime

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02816476

Layout table for location information
CHU d'Angers
Angers, France
CHU de Caen
Caen, France, 14000
CHU de Limoges
Limoges, France, 87042
CHU de Lyon Sud
Lyon, France
APHP - Necker
Paris, France
APHP - Saint Antoine
Paris, France
APHP - Saint Louis
Paris, France
CHU Poitiers
Poitiers, France
CHU de Rennes
Rennes, France
Amyloidosis Research and Treatment Center
Pavia, Italy
Sponsors and Collaborators
University Hospital, Limoges
Layout table for additonal information
Responsible Party: University Hospital, Limoges Identifier: NCT02816476    
Other Study ID Numbers: I15015/AMYDARA
First Posted: June 28, 2016    Key Record Dates
Last Update Posted: July 9, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunoglobulin Light-chain Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents